These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes. Peacock SC; Lovshin JA; Cherney DZI Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838 [No Abstract] [Full Text] [Related]
3. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Silva Dos Santos D; Polidoro JZ; Borges-JĂșnior FA; Girardi ACC Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Shehadeh N; Raz I; Nakhleh A Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893 [No Abstract] [Full Text] [Related]
5. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
6. Effects of sodium glucose co-transporter 2 inhibitors on the kidney. de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920 [TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Liu B; Wang Y; Zhang Y; Yan B Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521 [TBL] [Abstract][Full Text] [Related]
9. Sweet success? SGLT2 inhibitors and diabetes. Layton AT Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429 [No Abstract] [Full Text] [Related]
10. SGLT2 inhibitors: not every drug has the same effect. Staruschenko A Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073 [No Abstract] [Full Text] [Related]
11. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Vallon V Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005 [TBL] [Abstract][Full Text] [Related]
12. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Levine MJ Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042 [TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors for primary prevention of cardiovascular events. Raz I; Cernea S; Cahn A J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238 [No Abstract] [Full Text] [Related]
14. Dapagliflozine (Farxiga) for type 2 diabetes. Med Lett Drugs Ther; 2014 Feb; 56(1436):13-5. PubMed ID: 24663030 [No Abstract] [Full Text] [Related]
16. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. Kumar S; Khatik GL; Mittal A Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370 [TBL] [Abstract][Full Text] [Related]
17. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India. Ghosh A; Gupta R; Misra A J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074 [No Abstract] [Full Text] [Related]